Table 1.
Characteristics of patients ( n = 32) with relapsed or refractory B‐cell non‐Hodgkin's lymphoma who participated in this study
| Characteristic | No. | % |
|---|---|---|
| Total | 32 | 100 |
| Median age in years (range) | 54 (28–67) | |
| Male/female | 17/15 | 53/47 |
| Histology | ||
| Indolent | 17 | 53 |
| Follicular grade 1/2 | 17 | 53 |
| Aggressive | 15 | 47 |
| DLBCL | 11 | 34 |
| MCL | 2 | 6 |
| Large cell transformation of indolent lymphoma | 2 | 6 |
| ECOG performance status at entry | ||
| 0/1 | 30 | 94 |
| 2 | 2 | 6 |
| Stage at entry | ||
| 1 | 5 | 16 |
| 2 | 5 | 16 |
| 3 | 5 | 16 |
| 4 | 17 | 53 |
| LDH at entry | ||
| Normal | 18 | 56 |
| High | 14 | 44 |
| No. of sites of extranodal involvement | ||
| 0 | 13 | 41 |
| 1 | 14 | 44 |
| 2 or more | 5 | 16 |
| IPI score at study entry | ||
| 1 | 12 | 38 |
| 2 | 10 | 31 |
| 3 | 10 | 31 |
| No. of prior treatment regimens | ||
| 1 | 22 | 69 |
| 2 | 4 | 16 |
| 3 | 3 | 6 |
| 4 or more | 3 | 9 |
| Prior platinum‐containing therapy | 1 | 3 |
| Prior rituximab‐containing therapy | 20 | 63 |
| Prior radiation therapy | 4 | 13 |
| Prior radioimmunotherapy (90Yttrium‐ibritumomab) | 1 | 3 |
| Prior autologous stem cell transplant | 2 | 6 |
| Refractory to last chemotherapy | 10 | 31 |
| Relapsed disease | ||
| Previous remission duration ≤1 year | 8 | 25 |
| Previous remission duration >1 year | 14 | 44 |
DLBCL, diffuse large B‐cell lymphoma; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, Iactate dehydrogenase; MCL, mantle cell lymphoma.